Mark Mallon - Net Worth and Insider Trading

Mark Mallon Net Worth

The estimated net worth of Mark Mallon is at least $3 Million dollars as of 2024-11-13. Mark Mallon is the CEO of Ironwood Pharmaceuticals Inc and owns about 470,605 shares of Ironwood Pharmaceuticals Inc (IRWD) stock worth over $2 Million. Mark Mallon is also the CEO of NeoGenomics Inc and owns about 72,736 shares of NeoGenomics Inc (NEO) stock worth over $1 Million. Details can be seen in Mark Mallon's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Mallon has not made any transactions after 2021-12-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Mark Mallon

To

Mark Mallon Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Mallon owns 2 companies in total, including Ironwood Pharmaceuticals Inc (IRWD) , and NeoGenomics Inc (NEO) .

Click here to see the complete history of Mark Mallon’s form 4 insider trades.

Insider Ownership Summary of Mark Mallon

Ticker Comapny Transaction Date Type of Owner
IRWD Ironwood Pharmaceuticals Inc 2021-02-26 Executive Senior Advisor
NEO NeoGenomics Inc 2021-12-06 director & Chief Executive Officer

Mark Mallon Latest Holdings Summary

Mark Mallon currently owns a total of 2 stocks. Among these stocks, Mark Mallon owns 470,605 shares of Ironwood Pharmaceuticals Inc (IRWD) as of February 26, 2021, with a value of $2 Million and a weighting of 62.9%. Mark Mallon also owns 72,736 shares of NeoGenomics Inc (NEO) as of December 6, 2021, with a value of $1 Million and a weighting of 37.1%.

Latest Holdings of Mark Mallon

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IRWD Ironwood Pharmaceuticals Inc 2021-02-26 470,605 4.31 2,025,955
NEO NeoGenomics Inc 2021-12-06 72,736 16.43 1,195,052

Holding Weightings of Mark Mallon


Mark Mallon Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Mallon has made a total of 3 transactions in Ironwood Pharmaceuticals Inc (IRWD) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Ironwood Pharmaceuticals Inc is the sale of 30,675 shares on February 26, 2021, which brought Mark Mallon around $279,449.

According to the SEC Form 4 filings, Mark Mallon has made a total of 1 transactions in NeoGenomics Inc (NEO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in NeoGenomics Inc is the acquisition of 17,000 shares on December 6, 2021, which cost Mark Mallon around $520,710.

Insider Trading History of Mark Mallon

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Mallon Trading Performance

GuruFocus tracks the stock performance after each of Mark Mallon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Mallon is -38.25%. GuruFocus also compares Mark Mallon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Mallon within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Mallon's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Mallon

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -7.97 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -10.24 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark Mallon Ownership Network

Ownership Network List of Mark Mallon

No Data

Ownership Network Relation of Mark Mallon

Insider Network Chart

Mark Mallon Owned Company Details

What does Ironwood Pharmaceuticals Inc do?

Who are the key executives at Ironwood Pharmaceuticals Inc?

Mark Mallon is the Executive Senior Advisor of Ironwood Pharmaceuticals Inc. Other key executives at Ironwood Pharmaceuticals Inc include Principal Accounting Officer Ronald Silver , Chief Legal Officer Minardo John , and SVP & Chief Business Officer Andrew Davis .

Ironwood Pharmaceuticals Inc (IRWD) Insider Trades Summary

Over the past 18 months, Mark Mallon made no insider transaction in Ironwood Pharmaceuticals Inc (IRWD). Other recent insider transactions involving Ironwood Pharmaceuticals Inc (IRWD) include a net sale of 307,414 shares made by Thomas A Mccourt , a net sale of 81,739 shares made by Minardo John , and a net sale of 42,163 shares made by Andrew Davis .

In summary, during the past 3 months, insiders sold 0 shares of Ironwood Pharmaceuticals Inc (IRWD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 622,069 shares of Ironwood Pharmaceuticals Inc (IRWD) were sold and 53,676 shares were bought by its insiders, resulting in a net sale of 568,393 shares.

Ironwood Pharmaceuticals Inc (IRWD)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ironwood Pharmaceuticals Inc Insider Transactions

No Available Data

Mark Mallon Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Mallon. You might contact Mark Mallon via mailing address: C/o Ironwood Pharmaceuticals, Inc., 100 Summer Street, Suite 2300, Boston Ma 02110.